ITIH4 and infection: Consistent with this observation, high levels of co-receptor-directed, HIV-2 (+CD4) cross neutralizing antibodies were detected in 20 of 20 human serum samples from the VaxGen phase III clinical trial using monomeric gp120 [13], suggesting that during natural infection shed, soluble gp120 can elicit these antibodies [30].